2024
Evaluation of automated airway morphological quantification for assessing fibrosing lung disease
Pakzad A, Cheung W, Van Moorsel C, Quan K, Mogulkoc N, Bartholmai B, Van Es H, Ezircan A, Van Beek F, Veltkamp M, Karwoski R, Peikert T, Clay R, Foley F, Braun C, Savas R, Sudre C, Doel T, Alexander D, Wijeratne P, Hawkes D, Hu Y, Hurst J, Jacob J. Evaluation of automated airway morphological quantification for assessing fibrosing lung disease. Computer Methods In Biomechanics And Biomedical Engineering Imaging & Visualization 2024, 12: 2325361. DOI: 10.1080/21681163.2024.2325361.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis patientsDisease extentAbnormal airway dilatationCompared to healthy controlsFibrosing lung diseaseAirway segmentsVolumetric computed tomographyChest CTTraction bronchiectasisAirway dilationAirway measurementsLower lobePulmonary fibrosisAirway abnormalitiesLung diseaseHealthy controlsAirwayCT imagesImaging biomarkersClinical interpretationAirway branchingAutomated quantificationPatientsHealthy participants
2022
Quantifying morphological airway damage in idiopathic pulmonary fibrosis
Pakzad A, Cheung W, Quan K, Mogulkoc N, Van Moorsel C, Bartholmai B, Van Es H, Ezircan A, Van Beek F, Veltkamp M, Karwoski R, Peikert T, Clay R, Foley F, Braun C, Savas R, Sudre C, Doel T, Alexander D, Wijeratne P, Hawkes D, Hu Y, Hurst J, Jacob J. Quantifying morphological airway damage in idiopathic pulmonary fibrosis. 2022, 2547. DOI: 10.1183/13993003.congress-2022.2547.Peer-Reviewed Original Research
2019
Consistency of Automated Quantitation of Pulmonary Parenchymal Patterns on Normal, Low and Ultra-Low Dose CT
Braun C, Koo C, Foley F, Carmona Porquera E, Kalra S, Shaughnessy G, Egan A, Karwoski R, Peikert T, Rajagoplan S, Bartholmai B, Jacob J. Consistency of Automated Quantitation of Pulmonary Parenchymal Patterns on Normal, Low and Ultra-Low Dose CT. 2019, a4313-a4313. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4313.Peer-Reviewed Original Research
2018
Risk factors for pleural effusion recurrence in patients with malignancy
Grosu HB, Molina S, Casal R, Song J, Li L, Diaz‐Mendoza J, Reddy C, Yarmus L, Schiavo D, Simoff M, Johnstun J, Raid A, Feller‐Kopman D, Lee H, Sahetya S, Foley F, Maldonado F, Tian X, Noor L, Miller R, Mudambi L, Saettele T, Vial‐Rodriguez M, Eapen GA, Ost DE. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology 2018, 24: 76-82. PMID: 29966171, PMCID: PMC7315912, DOI: 10.1111/resp.13362.Peer-Reviewed Original ResearchConceptsMalignant pleural effusionRisk factorsFluid recurrenceMetastatic diseasePleural fluidHazards modelRecurrent symptomatic malignant pleural effusionsSymptomatic malignant pleural effusionRetrospective multicentre cohort studyFine-Gray subdistribution hazard modelPleural effusion recurrenceMulticentre cohort studyHazard of recurrenceCause-specific hazards modelPleural fluid cytologyChest X-rayPleural fluid LDHPleural effusion sizeSubdistribution hazard modelEffusion recurrenceFirst thoracentesisSymptom palliationCohort studyCumulative incidencePrimary outcome
2016
Computer-Aided Nodule Assessment and Risk Yield Risk Management of Adenocarcinoma: The Future of Imaging?
Foley F, Rajagopalan S, Raghunath SM, Boland JM, Karwoski RA, Maldonado F, Bartholmai BJ, Peikert T. Computer-Aided Nodule Assessment and Risk Yield Risk Management of Adenocarcinoma: The Future of Imaging? Seminars In Thoracic And Cardiovascular Surgery 2016, 28: 120-126. PMID: 27568149, PMCID: PMC5003324, DOI: 10.1053/j.semtcvs.2015.12.015.Peer-Reviewed Original ResearchConceptsSoftware applicationsNodule assessmentCase stepsPostsurgical patient outcomesComputer-Aided Nodule AssessmentIdentification of nodulesIndividualized patient managementAdjunctive therapyRisk stratificationAggressive tumorsFuture of ImagingPatient outcomesIndividualized managementPatient managementLung adenocarcinomaSuch methodsRelevant diagnostic toolRadiological surveillanceLung nodulesClinical useNoninvasive toolResearch effortsIntrarater variabilityAdenocarcinomaSemiquantitative measure
2015
1247
Thompson G, Foley F, Clain J, Escalante P. 1247. Critical Care Medicine 2015, 43: 313-314. DOI: 10.1097/01.ccm.0000475078.64175.1b.Peer-Reviewed Original ResearchA Rare Presentation of Tracheal Crystal-Storing Histiocytosis as Early Manifestation of Subglottic Mantle Cell Lymphoma
McCambridge A, Foley F, Kern R, Call T, Olson E. A Rare Presentation of Tracheal Crystal-Storing Histiocytosis as Early Manifestation of Subglottic Mantle Cell Lymphoma. CHEST Journal 2015, 148: 880a-880b. DOI: 10.1378/chest.2262151.Peer-Reviewed Original ResearchChlorhexidine Bathing Impact on Infections, Effect of Etomidate on Sepsis Mortality, and Evaluation of Ventilator-associated Conditions
Sasieta HC, Foley F, Batzlaff CM. Chlorhexidine Bathing Impact on Infections, Effect of Etomidate on Sepsis Mortality, and Evaluation of Ventilator-associated Conditions. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 1197-1199. PMID: 25978572, DOI: 10.1164/rccm.201503-0435rr.Peer-Reviewed Original Research
2012
The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: A pilot study
Silverman RA, Foley F, Dalipi R, Kline M, Lesser M. The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: A pilot study. Respiratory Medicine 2012, 106: 1096-1102. PMID: 22580235, DOI: 10.1016/j.rmed.2012.04.002.Peer-Reviewed Original ResearchConceptsAcute asthmaSevere acute asthmaSevere asthma episodesUse of rhDNasePrimary study endpointNon-fatal casesPost-randomization time pointsViscoelasticity of sputumBronchodilator therapyIpratropium treatmentPlacebo patientsSymptomatic asthmaticsFatal asthmaAdult asthmaticsClinical improvementMucous pluggingIll adultsStudy endpointStandardized careAsthma episodesEmergency departmentClinical trialsTherapeutic roleMucolytic agentTreatment groups